Results 1 to 10 of about 16,360 (195)

Psoriasiform Drug Eruption Caused by Abatacept: Immunohistochemical Investigation of STAT Signaling

open access: yesCase Reports in Dermatology, 2015
Abatacept is a biological immune modifier that is used for the treatment of rheumatoid arthritis. Although psoriasiform drug eruption is reported as one of the cutaneous adverse effects of abatacept, the precise mechanisms are not fully understood.
Kayo Tanita   +5 more
doaj   +2 more sources

Pneumocystis jirovecii Pneumonia in a Patient with Rheumatoid Arthritis Treated with Abatacept [PDF]

open access: yesCase Reports in Rheumatology, 2014
Rheumatoid arthritis (RA) is an autoimmune disease characterized by synovial membrane inflammation and joint cartilage destruction. Abatacept is a biologic agent that blocks the costimulation signals, preventing antigen presentation and proliferation of ...
Fabio E. Ospina   +4 more
doaj   +2 more sources

Abatacept enhances blood regulatory B cells of rheumatoid arthritis patients to a level that associates with disease remittance

open access: yesScientific Reports, 2021
Abatacept, an inhibitor of CD28 mediated T-cell activation, has been shown to be effective in controlling inflammation during rheumatoid arthritis (RA). However, its effects on immune regulatory B and T cells (Bregs and Tregs) has not been fully explored.
Maha Fahad Alenazy   +9 more
doaj   +1 more source

Outcomes in rheumatoid arthritis patients treated with abatacept: a UK multi-centre observational study

open access: yesBMC Rheumatology, 2021
Background Rheumatoid arthritis (RA) is an inflammatory autoimmune disease that causes chronic synovitis, resulting in progressive joint destruction and functional disability and affects approximately 400,000 people in the UK. This real-world study aimed
Ernest Choy   +9 more
doaj   +1 more source

Effects of CTLA4-Ig on human monocytes

open access: yesInflammation and Regeneration, 2017
Background Abatacept, a CTLA4-Ig fusion protein attenuates T cell activation by inhibiting the CD80/86-CD28 costimulatory pathway that is required for the proper T cell activation and thus displays beneficial effects in the treatment of rheumatoid ...
Toshihiro Tono   +5 more
doaj   +1 more source

RAISE – Rheumatoid Arthritis Independent Swiss Treatment Expectations and Outcome: results for the abatacept subpopulation

open access: yesSwiss Medical Weekly, 2013
QUESTIONS UNDER STUDY: Clinical trials do not necessarily reflect the results obtained in daily clinical practice. By conducting a non-interventional, observational study with biologics in rheumatoid arthritis (RA) patients in Switzerland, we aimed ...
Jean Dudler   +3 more
doaj   +1 more source

Preferable effect of CTLA4-Ig on both bone erosion and bone microarchitecture in rheumatoid arthritis revealed by HR-pQCT

open access: yesScientific Reports
This exploratory study aimed to examine the impact of abatacept treatment on bone structure in patients with rheumatoid arthritis (RA) using high-resolution peripheral quantitative computed tomography (HR-pQCT). RA patients initiating either abatacept or
Naoki Iwamoto   +12 more
doaj   +1 more source

Intranasal administration of abatacept enhances IL-35+ and IL-10+ producing Bregs in lung tissues of ovalbumin-sensitized asthmatic mice model.

open access: yesPLoS ONE, 2022
BackgroundsTreating asthmatic rheumatoid arthritis patients with abatacept has been shown to associate with better control of asthma symptoms. However, the mechanism behind that is not investigated.MethodsOvalbumin (OVA)- sensitized BALB/c female mice ...
Maha Fahad Alenazy   +15 more
doaj   +1 more source

Baseline serum levels of cross-linked carboxy-terminal telopeptide of type I collagen predict abatacept treatment response in methotrexate-naive, anticitrullinated protein antibody-positive patients with early rheumatoid arthritis

open access: yesRMD Open, 2022
Objective To investigate correlations between biomarkers of bone remodelling and extracellular matrix turnover with baseline disease activity and treatment response in patients with early rheumatoid arthritis (RA).Methods Assessing Very Early Rheumatoid ...
Roy Fleischmann   +12 more
doaj   +1 more source

Effect of abatacept versus conventional synthetic disease modifying anti-rheumatic drugs on rheumatoid arthritis-associated interstitial lung disease [PDF]

open access: yesThe Korean Journal of Internal Medicine
Background/Aims To compare the effects of abatacept and conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs) on the progression and development of rheumatoid arthritis-associated interstitial lung disease (RA-ILD).
Kyung-Ann Lee   +13 more
doaj   +1 more source

Home - About - Disclaimer - Privacy